Upstream therapy in patients with early atrial fibrillation the relevance of the routine versus aggressive upstream rhythm control for prevention of early atrial fibrillation in heart failure (race 3) study

Netherlands Heart Journal

Volumn 18, Issue 11, 2010, Pages 522-523

  van Gelder, I C ^a   Smit, M ^a   Alings, M ^b   Crijns, H J G M ^c  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b AMPHIA HOSPITAL   (Netherlands)

^c MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; ALDOSTERONE ANTAGONIST; ANGIOTENSIN II; ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ALDOSTERONE BLOOD LEVEL; ANGIOTENSIN BLOOD LEVEL; ANTIARRHYTHMIC ACTIVITY; ARTICLE; CLINICAL TRIAL; DIET RESTRICTION; DISEASE CONTROL; DRUG EFFICACY; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART REHABILITATION; HEART RHYTHM; HUMAN; NONHUMAN; ONSET AGE; PATHOGENESIS; PRIMARY PREVENTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SECONDARY PREVENTION; TREATMENT RESPONSE;

EID: 78649783385     PISSN: 15685888     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12471-010-0827-9     Document Type: Article

References (10)

1. Camm AJ, Kirchhof P, Lip GY, Schotten U, Savelieva I, Ernst S, et al. Guidelines for the management of atrial fibrillation: The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J 2010; doi:10.1093/eurheartj/ehq278.
2. Cosio FG, Aliot E, Botto GL, Heidbuchel H, Geller CJ, Kirch-hof P, et al. Delayed rhythm control of atrial fibrillation may be a cause of failure to prevent recurrences: reasons for change to active antiarrhythmic treatment at the time of the first detected episode. Europace. 2008;10:21-7.
3. Smit MD, Van Gelder IC. Upstream therapy of atrial fibrillation. Expert Rev Cardiovasc Ther. 2009;7:763-778.
4. Kourliouros A, Savelieva I, Kiotsekoglou A, Jahangiri M, Camm J. Current concepts in the pathogenesis of atrial fibrillation. Am Heart J. 2009;157:243-252.
5. Milliez P, Deangelis N, Rucker-Martin C, Leenhardt A, Vicaut E, Robidel E, et al. Spironolactone reduces fibrosis of dilated atria during heart failure in rats with myocardial infarction. Eur Heart J. 2005;26:2193-2199.
6. Shiroshita-Takeshita A, Brundel BJ, Burstein B, Leung TK, Mi-tamura H, Ogawa S, et al. Effects of simvastatin on the development of the atrial fibrillation substrate in dogs with congestive heart failure. Cardiovasc Res. 2007;74:75-84.
7. Piepoli MF, Davos C, Francis DP, Coats AJ. Exercise training meta-analysis of trials in patients with chronic heart failure (Ex-TraMATCH). BMJ. 2004;328:189.
8. Erbs S, Linke A, Gielen S, Fiehn E, Walther C, Yu J, et al. Exercise training in patients with severe chronic heart failure: impact on left ventricular performance and cardiac size. A retrospective analysis of the Leipzig Heart Failure Training Trial. Eur J Car-diovasc Prev Rehabil. 2003;10:336-344.
9. Mozaffarian D, Furberg CD, Psaty BM, Siscovick D. Physical activity and incidence of atrial fibrillation in older adults: the cardiovascular health study. Circulation. 2008;118:800-7.
10. Disertori M, Latini R, Barlera S, Franzosi MG, Staszewsky L, Maggioni AP, et al. Valsartan for prevention of recurrent atrial fibrillation. N Engl J Med. 2009;360:1606-1617.